FINWIRES · TerminalLIVE
FINWIRES

Barclays Upgrades Sandisk to Overweight From Equalweight, Adjusts PT to $2,300 From $1,200

By

Sandisk (SNDK) has an average rating of overweight and mean price target of $1,683.78, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

JPMorgan Upgrades FedEx to Overweight From Neutral, Adjusts Price Target to $460 From $432

FedEx (FDX) has an average rating of overweight and mean price target of $416.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$FDX
Research

Jefferies Downgrades Xiaomi to Underperform From Hold, Adjusts Price Target to HK$25.49 From HK$26.98

Xiaomi (HKG:1810) has an average rating of overweight and mean price target of HK$40.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$HKG:1810
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Eli Lilly And Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target to $1,255 from $1,225, 28.9x our 2027 EPS view, below LLY's five-year historical forward P/E average. We lift our 2026 EPS to $37.03 from $36.97 and raise our 2027 EPS to $43.42 from $42.22. We think LLY's continuous focus on external innovation to diversify its pipeline remains a key differentiator versus peers. LLY announced three vaccine deals today as part of a strategic push into infectious disease prevention. LLY is acquiring Curevo for up to $1.5B, gaining access to amezosvatein, a next-gen shingles vaccine that demonstrated comparable efficacy to the current standard while reducing side effects in Phase 2 trials. LLY is also acquiring LimmaTech Biologics for up to $780M, bringing a bacterial vaccine platform targeting antimicrobial-resistant pathogens. LLY is also acquiring Vaccine Company for up to $1.55B, adding an in vivo nanoparticle tech platform and a Phase 1-ready Epstein-Barr Virus vaccine candidate addressing a pathogen linked to multiple sclerosis and certain cancers.

$LLY